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Abstract
A Reversed-Phase Liquid Chromatographic (RP-LC) assay method was 
developed for the quantitative determination of atorvastatin calcium in the 
presence of its degradation products. The assay involved an isocratic elution of 
atorvastatin calcium in a LiChroCARTR 250*4 mm HPLC Cartridge LiChrospherR 
100 RP-18 (5 µm) column using a mobile phase consisting of 0.1% acetic acid 
solution: acetonitrile (45:55, v/v), pH = 3.8. The flow rate was 0.8 mL/min and the 
analytes monitored at 246 nm. The assay method was found to be linear from 
8.13 to 23.77 µg/mL. All the validation parameters were within the acceptance 
range. The developed method was successfully applied to estimate the amount 
of atorvastatin calcium in tablets.
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commercial formulations of the Argentinean market. The method was 
validated following the analytical performance parameters suggested 
by International Conference on Harmonization (ICH) [28]. 
Materials and Methods
Atorvastatin calcium trihidrate (98.8% calculated with reference 
to the dried substance) was purchased in Saporiti, Argentina. 
Acetonitrile and Methanol used were HPLC grade, Sintorgan (Buenos 
Aires, Argentina). Acetic acid was AR grade Sintorgan (Buenos Aires, 
Argentina). Distilled water was passed through a 0.45 µm membrane 
filter.
Equipment
The HPLC system consisted of a dual piston reciprocating Spectra 
Physics pump (Irvine, CA, United States, Model ISO Chrom. LC 
pump), a UV-Vis Hewlett Packard detector (Model 1050), a Hewlett 
Packard integrator (Loveland, CO, United States, Series 3395) and a 
Rheodyne injector (Model 7125).
Chromatographic conditions 
The experiment was performed on a LiChroCARTR 250*4 mm 
HPLC Cartridge LiChrospherR 100 RP-18 (5 µm) Merck (Darmstadt, 
Germany). The separation was carried out under isocratic elution 
with 0.1% acetic acid solution: acetonitrile (45:55, v/v), pH = 3.8. 
The flow rate was 0.8 mL/min. The wavelength was monitored at 246 
Introduction
Atorvastatin, 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β, 
δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)
carbonyl]-, calcium salt (2:1), trihydrate [R-(R*,R*)]-; (Figure 1) is 
a statin group medicine that reduces the level of serum cholesterol; 
thus it is used to treat hypercholesterolemia. Independent of 
the cholesterol-lowering property of statins they also have anti-
inflammatory and immunomodulating effects. It is rapidly absorbed 
from the gastro-intestinal tract. It has low absolute bioavailability 
of about 12% due to presystemic clearance in the gastro-intestinal 
mucosa and/or first pass metabolism in the liver, its primary site 
of action. Atorvastatin is metabolized by cytochrome P450 3A4 to 
a number of compounds which are also active inhibitors of HMG-
CoA reeducates. The mean plasma elimination half-life of inhibitory 
activity for HMG-CoA reeducates is approximately 20 to 30 hours 
due to the contribution of the active metabolites. It is 98% bound to 
plasma proteins. Atorvastatin is excreted as metabolites, primarily in 
the bile [1].
Several HPLC methods were reported in the literature for the 
quantitative determination of atorvastatin calcium in biological 
samples alone [2-4], and with another active drug substance [5-
9]. Most of the analytical techniques for atorvastatin calcium 
described in the literature are based on the liquid chromatographic 
determination of this drug alone in pharmaceutical formulations 
[10-13] with another active drug substance [14-18]. Other analytical 
techniques such as spectroscopy [19-23], MALDI Mass spectrometry 
imaging [24] electrochemical [25] and capillary electrophoresis [26] 
has also been described. A reversed phase LC with UV detection for 
the quantitation of atorvastatin calcium in bulk material is described 
in United States Pharmacopeia [27].
The purpose of this work was to develop a procedure for the 
quantitation of atorvastatin calcium and its separation, mainly, 
from its related substances. In addition, forced degradation studies 
of atorvastatin calcium were performed to provide an indication of 
the specificity of the method. The method was also applied to four 
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Figure 1: Atorvastatin Calcium.
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nm, and the injection volume was 20 µl. The HPLC was operated at 
ambient temperature. Under these conditions, the retention time (tR) 
of atorvastatin calcium was approximately 6.3 min. 
Preparation of standard solution
An accurately weighed quantity of 25 mg of atorvastatin calcium 
was placed into a 100 mL volumetric flask, dissolved in 5 mL of 
methanol and taken to volume with mobile phase. Then, 4 mL were 
withdrawn in a 100 mL volumetric flask. The volume was made with 
mobile phase (Conc 20 µg/mL). The solutions were passed through a 
0.45 µm nylon membrane filter before injection (25 mm disposable 
filter; Cat. N° R04SP02500 Osmonics Inc., Minnesota, USA).
Sample preparation
Approximately 25 mg of atorvastatin calcium raw material was 
placed into a 100 mL volumetric flask, dissolved in 5 mL of methanol 
and taken to volume with mobile phase. Then, 4 mL were withdrawn 
in a 100 mL volumetric flask. The volume was made with mobile 
phase (Conc 20 µg/mL). The solutions were passed through a 0.45 µm 
nylon membrane filter before injection (25 mm disposable filter; Cat. 
N° R04SP02500 Osmonics Inc., Minnesota, USA).
Preparation of comercial formulations
Twenty tablets were weighed and finely powered and an accurately 
weighed powder sample equivalent to one tablet was transferred to a 
50 ml volumetric flask; 10 ml of methanol was added and the flask was 
kept in an ultrasonic bath during 5 min. The mixture was then diluted 
to 50 ml with mobile phase. 1 mL was withdraw in a 10 mL volumetric 
flask and diluted to volume with mobile phase. The solutions were 
passed through a 0.45 µm nylon membrane filter before injection (25 
mm disposable filter; Cat. N° R04SP02500 Osmonics Inc., Minnesota 
USA).
Method validation
System suitability: The Relative Standard Deviations (RSD) 
values of the peak area, tailing factor, retention time, capacity and 
theoretical plates were the chromatographic parameters selected for 
the system suitability test [27].
Specificity: Forced degradation studies were performed to 
evaluate the specificity of the method. Degraded samples were 
prepared by refluxing 1.25 mg/mL atorvastatin calcium working 
standard with acid (1N hydrochloric acid), base (1N NaOH), water, 
30% hydrogen peroxide and refluxing for 1 hour. The drug was 
subjected to thermal degradation in solution state in a closed container 
in an oven at 80°C for 2 h and to photochemical degradation, (a 
solution was transferred to a container and exposed to daylight for 96 
h). After each degradation treatment, samples were allowed to cool at 
room temperature and diluted, to the same concentration as that of 
the standard solution, after being neutralized. Further, samples were 
analyzed using the methodology and the chromatographic conditions 
described.
Linearity: The linearity solutions were prepared at five 
concentrations levels from 40 % (w/v) to 125 % (w/v) of analytes 
concentration. Triplicate injections of 20 µL were made and 
chromatograph under the conditions described above. The drug was 
evaluated and peak areas were recorded. A calibration curve was 
plotted by taking the peak area on y-axis and respective concentration 
of drug on x-axis. The calibration curve was constructed and evaluated 
by its coefficient of determination (r2) and by least-squares linear 
regression analysis
Precision and accuracy: Six replicated of standard solution 
were analyzed to assess system precision. Both reproducibility and 
accuracy studies were evaluated by carrying out nine independent 
assays at concentration levels of 80, 100 and 120 % (w/v) (3 samples 
each) of a commercial formulation of atorvastatin calcium. The 
amount of atorvastatin calcium recovered was calculated. 
Robustness: The robustness was performed by deliberately 
changing the chromatographic conditions. The relative organic 
portion ratio of the eluent was varied by 45 to 55 %, while pH 
was adjusted to 2.8 and 4.3. The RSD, retention time, tailing, and 
theoretical plates were evaluated. 
Results and Discussion
The described reverse-phase liquid chromatography method 
was developed to provide a rapid quality control determination 
of atorvastatin calcium in tablets. Validation of the method was 
performed according to ICH. This method uses a simple mobile 
phase. All samples were analyzed using the assay chromatographic 
conditions described. 
The analytical column was equilibrated with the eluting solvent 
system used. After an acceptably stable baseline was achieved, the 
standards and then the samples were analyzed. 
The system suitability results were calculated according to 
the USP 35 <621> (27) from typical chromatograms. The system 
precision is a measure of the method variability that can be expected 
for a given analyst performing the analysis and was determined 
by performing six replicate analyses of the same working solution. 
The Relative Standard Deviation (RSD) obtained was 0.6%. Peak 
asymmetry or tailing factor, T, was calculated as T=W0.05/2f; where 
W0.05 is the distance from the leading edge to the tailing edge of the 
peak, measured at 5% of the peak height from the baseline and f is the 
distance from the peak maximum to the leading edge of the peak. The 
tailing factor did not exceed 1.5 The RSD of peak area response and 
retention time showed the satisfactory repeatability of the system (< 
1.5%) (Table 1).
Degradation was indicated in the stressed sample by a decrease 
in the expected concentration of the drug and increased levels of 
degradation products. Atorvastatin calcium was degraded to different 
products under acid, base, oxidation, hydrolysis and photolysis (Table 
2). In addition, there was no interference regarding the retention time 
of atorvastatin calcium and its degradation products. 
Parameter Minimun value Maximun value Average RSD (%) 
Retention time 6.292 6.331 6.312 0.44
Area 6924058 7088160 7006109 1.66
Capacity 2.146 2.165 2.155 0.62
Asimetry factor 0.98 1.00 0.99 1.43
Theoretical plates 2534 2565 2550 0.86
Table 1: System Suitability.
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The linearity of the HPLC method was determined by analysis of 
three replicates of five concentrations of standard solutions (ranging 
from 8.13 and 23.77 µg/mL). The calibration curve showed good 
linearity over the concentration range. The correlation coefficient 
(“r”) value was 0.9994. Typically, the regression equation for the 
calibration curve was found to be y = 369342.9x – 109051.8. The 
linearity of the calibration graphs was validated by the high value 
of the correlation coefficient and the intercept value that was not 
statistically (p = 0.05) different from zero (Figure 2 and Table 3). 
The precision is usually expressed as the RSD of a series of 
measurements. The reproducibility and accuracy studies were 
evaluated by recovery studies with 9 samples of one commercial 
formulation studied (n = 3 for 80%, 100% and 120%) indicated that 
the mean recovery was 99.4 %, and the RSD was 0.63%.
Method accuracy was also demonstrated by plotting the amount 
of atorvastatin calcium found against the amount present in the 
sample, both expressed in mg. Linear regression analysis rendered 
slopes not significantly different from 1 (t test p=0.05), intercepts not 
significantly different from zero (t test p=0.05), and r = 0.9992. The 
experimental t of the recovery percentage was also studied, showing a 
value of 2.00, below the 2.306 established in the tabulated t (95% level 
of probability, 8d.f) (Table 4).
The robustness of an analytical procedure is a measure of its 
capacity to remain unaffected by small, but deliberate variations 
in method parameters, and provides an indication of its reliability 
during normal usage.
Robustness of the method was investigated under a variety of 
conditions including changes of pH and percentage of acetonitrile in 
the mobile phase. 
The effect on retention time, theoretical plates and tailing factor 
can be seen in Table 5. A decrease in acetonitrile proportion increases 
both retention time and theoretical plates. It was found that retention 
time of atorvastatin calcium ranges from 0.3 cm/min by pH changes.
The results of the evaluation of the four market products can be 
in Table 6.
Conclusion
A straightforward, specific, linear, precise and accurate RP-
HPLC method has been developed and validated for quantitative 
determination of atorvastatin calcium in tablets. The method is very 
simple and specific, as the peak is well separated from its impurities, 
which makes it especially suitable for routine quality control analysis 
work. 
Figure 2: Linearity of the method.
Condition Time(h)
% of 
Atorvastatin
RRT of degradation 
products
Acid (1 N HCl, reflux) 1 18.5 1.34, 1.43, 2.14
Base (1 N NaOH, reflux) 1 79.3 0.39, 0.46, 0.57
Hydrogen peroxide 100 vol 
(reflux)
1 7.8 0.33, 0.43, 0.72, 0.78, 1.68, 2.90
Water (reflux)    1 85.9 0.38
Heat dry, 80°C (solution)    2 97.9 Non detected
Daylight exposure   96 56.6 0.77, 1.35, 1.64
Table 2: Selectivity.
* RRT: Relative Retention Time
% of nominal 
value Concentration (µg/mL)
Average peak area 
response 
RSD
%
40 8.13 2938581 0.6
60 11.88 4266208 1.2
80 16.26 5889101 0.9
100 19.42 6949213 0.3
125 23.77 8759624 0.1
Slopea 369342.9 ± 929563,0
Interceptb -109051.8 ± 15630862,6
Table 3: Linearity.
aConfidence limits of the slope (p=0.05)
bConfidence limits of the intercept (p= 0.05)
% of nominal 
value
Added  
Amount
(mg)
Found 
amount
 (mg)
Recovery
(%)
Average 
recovery
(n=3)
RSD
(%)
80
20.2
20.8
21.0
20.1
20.5
20.7
99.5
98.8
98.6
99.0 0.48
100
26,2
25.2
24.7
26.1
24.8
24.7
99.7
98.5
100.0
99.4 0.80
120 31.130.2
29.7
31.4
30.2
29.5
100.1
100.0
99.5
99.9 0.32
Mean (n=9) 99.4 0.63
Table 4: Precision and Accuracy.
Mobile Phase RT Tailing factor N
0.1% Acetic Acid solution –Acetonitrile (45:55, 
v/v) pH: 3.8 6.30 1.11 2545
0.1% Acetic Acid solution - Acetonitrile (45:55, 
v/v) pH: 2.8 6.57 1.00 2767
0.1% Acetic Acid solution - Acetonitrile (45:55, 
v/v) pH: 4.3 6.01 1.00 2312
0.1% Acetic Acid solution - Acetonitrile (55:45, 
v/v) 15.24 1.33 14865
0.1% Acetic Acid solution - Acetonitrile (50:50, 
v/v) 9.16 1.00 5365
Table 5: Robustness.
Brand Average % RSD% 
 A  92.1 1.11
 B  105.0 0.53
 C  92.9 1.54
 D  98.6 0.82
Table 6: Commercial formulations assay.
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